Business & Industry News Channel
AstraZeneca, and its global biologics research and development arm MedImmune, announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company's oncology portfolio and bringing new medicines to patients more quickly. 
Alcon, the global leader in eye care and a division of Novartis, announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve cataract surgery for surgeons and patients. 
Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of 
Boehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 2018, October 15 the company would like to draw attention to the hygienic conditions in the impoverished regions around the world. Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humira®* (adalimumab). 
Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, Germany.